Desmopressin is indicated for the treatment of central diabetes insipidus, primary nocturnal enuresis, and nocturia due to nocturnal polyuria. It is a synthetic analogue of vasopressin with selective action on V2 receptors, leading to increased water reabsorption in the kidneys and reduced urine production. Its key advantage is targeted antidiuretic effect without significant vasoconstrictive activity, ensuring effective control of symptoms with a favorable safety profile. In clinical practice, desmopressin helps restore fluid balance, reduce excessive urination, and improve quality of life, especially in patients with sleep disruption due to nocturia. Oral tablet formulation allows convenient and controlled long-term therapy. Its predictable efficacy and ease of use make it a standard treatment option in endocrine and urological conditions.